Evidence map›Paper›PMID 35907999›Full record

ArticleChinese medicine2022

Integrated strategy of network analysis prediction and experimental validation to elucidate the possible mechanism of compound Turkish gall ointment in treating eczema.

Xuan Ma, Meng Hao, Ming Hui Zhang, Ya Zeng, Qing Qing Yang, Lu Zhao, Chen Yang Fan, Zhi Hong Ji, Ke Ao Li, Zhi Jian Li and 2 more

Open access · goldAbstract read
In one paragraph

Article in Chinese medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
2.8field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Xuan MaCollege of Pharmacy, Xinjiang Medical University, Xinjiang, Urumqi, 830011, China.
Meng HaoXinjiang Qimu Medical Research Institute, Xinjiang, Urumqi, 830002, China.
Ming Hui ZhangXinjiang Qimu Medical Research Institute, Xinjiang, Urumqi, 830002, China.
Ya ZengXinjiang Qimu Medical Research Institute, Xinjiang, Urumqi, 830002, China.
Qing Qing YangXinjiang Qimu Medical Research Institute, Xinjiang, Urumqi, 830002, China.
Lu ZhaoXinjiang Qimu Medical Research Institute, Xinjiang, Urumqi, 830002, China.
Chen Yang FanXinjiang Qimu Medical Research Institute, Xinjiang, Urumqi, 830002, China.
Zhi Hong JiXinjiang Key Laboratory of Generic Technology of Traditional Chinese Medicine (Ethnic Medicine) Pharmacy, Xinjiang, Urumqi, 830002, China.
Ke Ao LiXinjiang Qimu Medical Research Institute, Xinjiang, Urumqi, 830002, China.
Zhi Jian LiXinjiang Uygur Medical Research Institute, Xinjiang, Urumqi, 830011, China.
Mirzat MaimaitiXinjiang Qimu Medical Research Institute, Xinjiang, Urumqi, 830002, China.
Ji Hong NieDepartment of Pharmacy, Affiliated Hospital of Traditional Chinese Medicine, Xinjiang Medical University, Xinjiang, Urumqi, 830011, China. xjnjh411@163.com.
Xinjiang Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCompound Turkish gall ointment (CTGO) has a long history of being widely used as a folk medicine in Xinjiang for the treatment of eczema. CTGO is currently in the pre-investigational new drug application stage, but its pharmacological mechanisms of action have not yet been clarified.

methodsFirst, a sensitive and reliable ultra-high performance liquid chromatography-Q exactive hybrid quadrupole-orbitrap high-resolution accurate mass spectrometry (UHPLC-Q-Orbitrap HRMS) technique was established. Second, an integrative strategy of network analysis and molecular docking based on identified and retrieved ingredients was implemented to investigate the potential targets and pathways involved in the treatment of eczema with CTGO. Finally, Sprague-Dawley (SD) rats with eczema were prepared to verify the predicted results. The skin conditions of the rats were observed, evaluated, and scored. Skin tissues were observed by hematoxylin-eosin (HE) staining, and the levels of serum interferon-γ (IFN-γ) and interleukin-4 (IL-4) were determined by enzyme-linked immunosorbent assay (ELISA). The expression levels of toll-like receptor 4 (TLR4), nuclear factor kappa-B p65 (NF-κB p65), interleukin-1β (IL-1β), and tumor necrosis factor-α (TNF-α) were detected by real-time quantitative polymerase chain reaction (RT-qPCR).

resultsA total of 29 compounds were identified. We found 38 active components and 58 targets for the treatment of eczema, which included 118 signaling pathways related to inflammation, immunity, and apoptosis. CTGO significantly improved the skin surface and histopathological characteristics of eczema-affected rats, downregulated the expression of IL-4, TLR4, NF-κB (p65), IL-1β, and TNF-α, and upregulated the expression level of IFN-γ.

conclusionWe predicted and validated our prediction that CTGO may be used to treat eczema by affecting the TLR4/NF-κB signaling pathway, which provides guidance for future experimental studies.

Indexed as

CTGOEczemaHPLC fingerprintNetwork analysisTLR4/NF-κB signaling pathway

Identifiers

PMID35907999
PMCPMC9338667
OpenAlexW4288749553

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.